Senate plans Tuesday healthcare vote—but doesn’t know what bill will be considered

Senate Republican leaders are pushing for a July 25 vote on some form of legislation to repeal the Affordable Care Act, but haven’t decided on what will be in the bill.

The 50 votes need to pass a bill haven’t materialized on either the Republicans’ ACA replacement, the Better Care Reconciliation Act, or a revived strategy to repeal the ACA and give themselves two years to craft an alternative. The BCRA would cause 22 million more people to be uninsured by 2026 and raise an individual’s deductibles for benchmark plans to $13,000, while repeal-and-delay would grow the number of uninsured by 32 million, according to the Congressional Budget Office.

When asked if senators would know in advance what they’d voting on Tuesday, Sen. John Cornyn, R-Texas, said, “That’s a luxury we don’t have,” according to the Associated Press.

In an effort to win over skeptical Republicans, leaders are floating several proposals to add new funds to the bill, like letting states use Medicaid funds to help people buy their own private health insurance.

Read the full article at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.